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Background
R e p o r t so fh e t e r o z y g o u sc a r r i e r so faMEFV mutation
presenting a FMF phenotype are increasing, but no data
is available on the outcome of FMF heterozygous
children.
Aim
To assess the relevancy of clinical diagnosis of FMF in
heterozygous children before the age of 6.
Methods
We performed a retrospective single-centre study of 29
patients diagnosed with FMF before the age of 6, who
had only 1 mutation in the MEFV gene, compared to a
group of 26 homozygous or compound heterozygous
patients in whom the diagnosis of FMF was also made
during early childhood.
Results
Presenting signs in heterozygous children did not differ
from homozygous or compound heterozygous patients.
Initial response to colchicine was identical in the two
groups. During follow-up heterozygous patients were
more likely to have a milder course of the disease. After
puberty clinical signs of FMF totally disappeared in 6/11
heterozygous patients. In these 6 patients, colchicine
could be withdrawn without recurrence of symptoms or
rise of inflammatory markers. If applied after puberty,
clinical diagnostic criteria sets were no longer positive
in these 6 patients, whereas the same criteria applied
retrospectively during early childhood concluded to
FMF.
Conclusion
Our study suggests that the diagnosis of FMF in very
young heterozygous children should be cautious. Het-
erozygous children can present with an FMF-like disease
during early childhood that may disappear with age,
while others will suffer lifelong from their disease. Only
a careful follow-up of FMF heterozygotes allows an
accurate diagnosis over time.
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